Comparative Study of Treatment Costs and Surgical Outcomes Between Energy Devices and Monopolar Devices in Resectable Non-Small Cell Lung Cancer: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20241119001

Enrollment

Registered

2024-11-19

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer Energy Devices, Monopolar Devices, Resectable Non-Small Cell Lung Cancer, Treatment Costs, Surgical Outcomes

Interventions

Intervention Group: Lobectomy performed using an energy device. ,Control Group: Lobectomy performed using a monopolar device.

Experimental Device,Experimental Device

Energy device,Monopolar device

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 20 years or more, with histologically confirmed resectable NSCLC. 2. Patients eligible for lobectomy and systematic lymph node dissection based on standard clinical guidelines. 3. No prior history of thoracic surgery. 4. ECOG performance status 2 or less. 5. Written informed consent provided.

Exclusion criteria

Exclusion criteria: 1. Patients with metastatic disease or advanced-stage cancer not suitable for lobectomy. 2. Patients with severe comorbidities included patients with ASA 3 and 4 operative risk that could impact surgical outcomes. 3. Patients who receive induction therapy (systemic +/- radiotherapy) before planning to surgery due to these could affect tissue quality and bleeding risk. 4. Pregnant or breastfeeding women. 5. Patients who on anticoagulant therapy. We exclude all patients who have severe comorbidities or anticoagulant therapy that could increase the risk of lymphatic leakage or bleeding. 6. Patients with benign diseases, requiring conversion to thoracotomy, undergoing extensive resections due to these patients have high risk for bleeding.

Design outcomes

Primary

Measure	Time frame
Total cost of treatment within hospitalization of surgery Direct Medical Cost, Indirect Costs	—

Secondary

Measure	Time frame
Operative time, Perioperative finding and complications, Length of hospital stay (day) within hospitalization of surgery Operative time (minutes), Length of hospital stay (day)	—

Countries

Thailand

Contacts

Public ContactApichat Tantraworasin

Chaing Mai University

researchsurg.submit@gmail.com0896336342

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026